Shachi B. Patel

Pediatrics

3030 Harden Blvd
Lakeland, FL 33803

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance.

Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance.

Journal: Circulation. Population health and outcomes

Published: June 22, 2026

Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with Both SGLT2i and ARNI.

Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with Both SGLT2i and ARNI.

Journal: Journal of cardiac failure

Published: January 01, 2026

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial.

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial.

Journal: Cardiovascular diabetology

Published: April 28, 2025

Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The REALIZE-K open-label run-in phase.

Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The REALIZE-K open-label run-in phase.

Journal: European journal of heart failure

Published: April 24, 2025

Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.

Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.

Journal: European journal of heart failure

Published: April 12, 2025

Orthostatic Pulse Pressure as a Potential Indicator of Preload Insufficiency in HFpEF: Insights From PRESERVED-HF.

Orthostatic Pulse Pressure as a Potential Indicator of Preload Insufficiency in HFpEF: Insights From PRESERVED-HF.

Journal: JACC. Heart failure

Published: April 08, 2025

Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.

Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.

Journal: JACC. Heart failure

Published: March 11, 2025

Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.

Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.

Journal: JACC. Heart failure

Published: February 18, 2025

Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HF.

Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HF.

Journal: ESC heart failure

Published: November 15, 2024

Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure.

Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure.

Journal: Journal of the American College of Cardiology

Published: October 28, 2024

Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.

Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.

Journal: Circulation. Heart failure

Published: October 18, 2024

Impact of sleep apnea treatment on cardiometabolic parameters in a large national multicenter alliance registry.

Impact of sleep apnea treatment on cardiometabolic parameters in a large national multicenter alliance registry.

Journal: American journal of preventive cardiology

Published: September 11, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026